Hugel restructures US Letybo sales for pricing control as Q3 revenue seen falling 26.3% sequentially

DB Securities' forecast puts 68 billion won of the 90 billion won revenue increase between 2027 and 2028 into operating profit, an incremental margin of 75.6% ^[3]. The step before it, from this year into 2027, turns 111 billion won of extra revenue into 44 billion won of extra profit, or 39.6% ^[4]. Full-year operating margin on the same numbers runs 38.8%, then 38.9%, then 43.6% ^[5]. None of this is company guidance; DB built the estimates after the investor day on the 18th ^[4].

Direct recognition does that to an income statement. The same vial is booked at what the end customer pays instead of at the price Benev paid for it, and Benev is paid a commission on the sale ^[3]. DB expects the switch to improve Hugel's average selling price and to give it the customer data Benev holds, with the cost of acquiring that data capitalised as an intangible and amortised afterwards ^[6][7]. The note does not put a number on the commission rate or on the data.

The bill lands first. Working back from DB's third-quarter estimate, June-quarter revenue was roughly 137.9 billion won ^[1]. Operating profit of 36 billion won on the September quarter is a 35.4% margin ^[2]. Export revenue takes the harder hit, down 29.1% from a year earlier to 32.3 billion won, about 31.8% of the quarter's total ^[9][6].

For anyone modelling the US business, the awkward part is the base. From the second half of 2027 Hugel measures US toxin revenue at a different point in the chain than it did this year ^[1][3]. A 2027-over-2026 growth rate therefore blends two definitions of revenue, and whether Letybo moved more vials in the United States has to come from a unit disclosure rather than from the top line. DB's two-year forecast implies 40.0% revenue growth from this year to 2028 ^[7]; how much of that is price recognition and how much is volume is not separable from the figures published.

I'd take the price-capture case, with a condition: it pays only if the end-customer price beats the old supply price by more than the commission and the amortisation combined, and the 39.6% incremental margin DB models for 2027 is roughly what a year of paying both looks like ^[4]. The counter-argument is that Hugel is also taking on the US selling operation Benev was running, and the commission through the first half of 2027 is the price of renting it back while Hugel builds its own ^[2][5]. If the price gap is thin, the first forecast to break is the 43.6% operating margin in 2028, nearly five points above this year's 38.8% ^[5].